A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)
Study sponsor: Supernus Pharmaceuticals, Inc. · SUPN
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-09-04Actual
Enrollment · participants189Actual
Source updated2025-09-15Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.